west virginia tirzepatide lawsuit A class-action has been filed against CVS Caremark over its decision to stop covering Zepbound, Eli Lilly's blockbuster GLP-1 drug to treat obesity. When the major pharmacy benefit manager informed patients Lilly asks to join lawsuit

Description

Proper dose titration reduces the severity of these effects

extensive post-market safety data

The most commonly reported side effects include: Nausea : Affecting 12% to 24% of patients with type 2 diabetes and 24% to 31% in weight management trials Diarrhea : 12% to 17% in diabetes trials and 18% to 23% in weight management trials Decreased appetite : 5% to 10% of patients Vomiting : 5% to 10% in diabetes trials and 8% to 12% in weight management trials Constipation : 5% to 7% in diabetes trials and 16% to 17% in weight management trials Dyspepsia : 5% to 9% of patients Abdominal pain : 5% to 9% of patients Alopecia (hair loss) : Reported in weight management trials These symptoms are typically mild to moderate in severity, occur most commonly during dose escalation, and tend to diminish over time as patients develop tolerance

And while the study compared GLP-1 RAs broadly (not tirzepatide specifically), tirzepatide is a GLP-1 RA with additional GIP activity that may confer extra cardiovascular benefit